SOPHiA GENETICS to Present at the 40th Annual J.P. Morgan Healthcare Conference
12/29/2021 - 07:00 AM
BOSTON and LAUSANNE, Switzerland, Dec. 29, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial Officer Ross Muken, will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. The virtual presentation will begin at 8:15 a.m. ET/2:15 p.m. CET on Tuesday, January 11, 2022 and will be available live and archived on SOPHiAGENETICS.COM , in the Investor Relations section.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM , or connect on Twitter , LinkedIn and Instagram . Where others see data, we see answers.
Investor Contact: Jennifer Pottage Head of Investor RelationsJpottage@sophiagenetics.com
Media Contact: Eliza Bamonti Director of Public RelationsEbamonti@sophiagenetics.com
SOPH Rankings
#276 Ranked by Stock Gains
SOPH Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
About SOPH
sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based